Inhibikase Begins Pivotal Phase 3 Trial in PAH

An announcement from Inhibikase Therapeutics ( (IKT) ) is now available.

On April 7, 2026, Inhibikase Therapeutics announced it had enrolled the first patient in its global pivotal Phase 3 IMPROVE-PAH study of IKT-001 for the treatment of Pulmonary Arterial Hypertension. The trial’s launch marks a significant operational milestone for the company as it seeks to accelerate the path toward a potential regulatory filing for its lead candidate.

The IMPROVE-PAH trial uses a two-part adaptive design with a 12-week dose-titration phase, initially measuring change in pulmonary vascular resistance in about 140 patients, then focusing on six-minute walk distance in roughly 346 additional patients. Clinicians involved in the study highlighted the persistent progression of PAH despite multiple existing therapies and emphasized that the trial is structured to capture outcomes that matter most to patients and physicians, potentially strengthening Inhibikase’s position in the PAH treatment landscape.

The most recent analyst rating on (IKT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Inhibikase Therapeutics stock, see the IKT Stock Forecast page.

Spark’s Take on IKT Stock

According to Spark, TipRanks’ AI Analyst, IKT is a Neutral.

IKT scores low primarily due to weak financial performance (minimal revenue, widening losses, and ongoing cash burn) and bearish technicals (trading below key moving averages with negative MACD and weak momentum). A strong, low-debt balance sheet provides some offset, while valuation is difficult to assess meaningfully due to negative earnings and no dividend data.

To see Spark’s full report on IKT stock, click here.

More about Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapeutics to modify the course of cardiopulmonary diseases, with a primary emphasis on Pulmonary Arterial Hypertension, a progressive, life-threatening orphan condition affecting about 50,000 Americans. Its lead product candidate is IKT-001, a novel oral prodrug of imatinib mesylate intended to leverage imatinib’s long-established safety profile while reducing gastrointestinal side effects.

The company is pursuing a single pivotal global Phase 3 clinical study, IMPROVE-PAH, across roughly 180 sites worldwide to evaluate IKT-001 in PAH, targeting key hemodynamic and functional outcomes. By concentrating on aberrant signaling through type III receptor tyrosine kinases, including platelet-derived growth factor receptors and c-Kit, Inhibikase aims to address an unmet need in PAH where many patients continue to experience disease progression despite existing therapies.

Average Trading Volume: 1,873,206

Technical Sentiment Signal: Sell

Current Market Cap: $236.3M

See more insights into IKT stock on TipRanks’ Stock Analysis page.